hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06385314 id: Degirmenci1499 briefTitle: A Cross Sectional Study on Dental Anxiety and State Anxiety Related to Removal of Fixed Partial Dentures overallStatus: COMPLETED date: 2022-09-05 date: 2023-11-25 date: 2023-12-29 date: 2024-04-26 date: 2024-04-26 name: Abant Izzet Baysal University class: OTHER briefSummary: This study aims to evaluate the effect of the clinical removal of fixed partial dentures (FPDs) on oral health-related quality of life (OHRQoL) and the anxiety values of individuals and to determine the risk factors of high anxiety levels. 300 participants were included in this study. Six different reasons for the clinical removal of FPDs (oral examination, denture renewal, root canal treatment, tooth extraction, periodontal treatment, and composite filling restoration) were defined. Questions pertaining to the United Kingdom Oral Health-Related Quality-of-Life Measure (OHQoL-UK), the Modified Dental Anxiety Scale (MDAS), and the Spielberger State-Trait Anxiety Inventory - State (STAI-S) and Trait (STAI-T) were answered. conditions: Dental Anxiety studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: CROSS_SECTIONAL count: 300 type: ACTUAL name: Collecting data with oral health related quality of life, dental anxiety and state anxiety measure: United Kingdom Oral Health-Related Quality-of-Life Measure measure: Modified Dental Anxiety Scale measure: Spielberger State Anxiety Inventory measure: Spielberger Trait Anxiety Inventory sex: ALL minimumAge: 30 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Kubra Degirmenci city: Bolu country: Turkey lat: 40.73583 lon: 31.60611 hasResults: False
nctId: NCT06385301 id: Lung_disease_6MWD_SOT briefTitle: Exercise Performance on Ambient Air vs. Low-Flow Oxygen Therapy With Chronic Lung Diseases overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2025-05 date: 2025-11 date: 2024-04-26 date: 2024-04-26 name: University of Zurich class: OTHER briefSummary: The investigators aim to study the effect of SOT in subjects with chronic lung disease in submaximal exercise. conditions: Lung Disease Chronic conditions: Lung Diseases, Interstitial conditions: Lung Diseases, Obstructive studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: Each participant is its own control primaryPurpose: OTHER masking: NONE count: 14 type: ESTIMATED name: 6-minute walk distance (6MWD) test on ambient air name: 6-minute walk distance test with supplemental oxygen (approximately 3l/min, nasal) measure: 6-minute walk distance (6MWD) with supplemental oxygen therapy (SOT) vs. ambient air measure: SpO2 at rest and peak 6MWD with SOT vs. ambient air measure: Heart rate at rest and peak 6MWD with SOT vs. ambient air measure: Borg dyspnea scale at rest and peak 6MWD with SOT vs. ambient air measure: Borg leg fatigue scale at rest and peak 6MWD with SOT vs. ambient air measure: Blood pressure at rest and peak 6MWD with SOT vs. ambient air sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University Hospital Zürich city: Zurich zip: 8091 country: Switzerland name: Silvia Ulrich, Prof. Dr. role: CONTACT phone: 0041 44 255 22 20 email: silvia.ulrich@usz.ch name: Mona Lichtblau, Dr. role: CONTACT phone: +41442552220 email: mona.lichtblau@usz.ch name: Silvia Ulrich, Prof. Dr. role: PRINCIPAL_INVESTIGATOR lat: 47.36667 lon: 8.54999 hasResults: False
nctId: NCT06385288 id: 268/2021BO2 briefTitle: Blood and Tissue Extraction for Immunological Examinations During Neoadjuvant Therapy of Soft Tissue Sarcomas overallStatus: RECRUITING date: 2021-07-21 date: 2026-07-21 date: 2031-07-21 date: 2024-04-26 date: 2024-04-26 name: University Hospital Tuebingen class: OTHER briefSummary: "Blood and Tissue Extraction for Immunological Examinations During Neoadjuvant Therapy of Soft Tissue Sarcoma" is a prospective study with additional translational research using preoperative and postoperative tissue, blood sampling and advanced imaging. conditions: Soft Tissue Sarcoma Adult studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: OTHER masking: NONE maskingDescription: Open Label count: 30 type: ESTIMATED name: Blood and tissue collection for immunological studies, advanced imaging. name: neoadjuvant Therapy measure: Description of the cellular immune status via flow-cytometrie from collected blood samples measure: Description of the cellular immune status on tissue samples ussing komplex immunohistochemie measure: Measurement of the cellular free DNA from collected blood samples measure: Measurement of HMGB1 from collected blood samples measure: Evaluation of morphological tumor characteristics (size, diffusion) with weekly MRIs sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University Hospital Tuebingen status: RECRUITING city: Tübingen state: Baden-Württemberg zip: 72076 country: Germany name: Vlatko Potkrajcic, MD role: CONTACT phone: +49 7071 29 phoneExt: 82165 email: Vlatko.potkrajcic@med.uni-tuebingen.de name: Cihan Gani, MD role: CONTACT phone: +49 7071 29 phoneExt: 82165 email: cihan.gani@med.uni-tuebingen.de lat: 48.52266 lon: 9.05222 hasResults: False
nctId: NCT06385275 id: H-44897 briefTitle: The Role of Vitamin K on Knee Osteoarthritis Outcomes overallStatus: NOT_YET_RECRUITING date: 2024-07 date: 2026-12 date: 2026-12 date: 2024-04-26 date: 2024-04-26 name: Boston University class: OTHER name: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) briefSummary: The appropriate form and dosing of vitamin K to benefit relevant outcomes in knee osteoarthritis (OA) are not known. In intervention studies for conditions other than knee OA (e.g., prevention of cardiovascular disease), the most commonly used forms and doses include phylloquinone (vitamin K1; 1000µg or 500µg daily) or menaquinone-7 (MK-7 or vitamin K2; 360µg daily). However, whether these doses are adequate to increase vitamin K to levels that ameliorate risk of adverse OA outcomes is not known. Furthermore, although some studies suggest enhanced bioavailability of MK-7 over vitamin K1, as well as extra-hepatic effects, whether this is relevant for an older population with knee OA is not known,
The overall goal of this pilot randomized clinical trial (RCT) is to test different subtypes and doses of vitamin K supplementation in older adults with knee OA and to measure changes in relevant biochemical measures. conditions: Osteo Arthritis Knee studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: A stratified permuted block randomization will be used to assign 55 participants in a 1:1:1:1 ratio to each intervention arm. A random allocation sequence will be generated by computer in blocks of 4 or 8, stratified by sex and race. primaryPurpose: TREATMENT masking: TRIPLE maskingDescription: Use of a placebo from Johnson Compounding Pharmacy (Waltham, MA) of similar appearance and taste to the vitamin K supplements will allow for masking of participants, the study PI, and other study team members to the treatment allocation. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR count: 55 type: ESTIMATED name: Vitamin K1 500 µg name: K1 1000 µg name: Vitamin K2 (MK-7) 360 µg name: Placebo measure: Change in uncarboxylated matrix Gla protein (ucMGP) levels measure: Change in phylloquinone levels measure: Sufficient phylloquinone levels measure: Change in menaquinone-7 (MK-7) levels measure: Study adherence measure: Participant acceptability of intervention sex: ALL minimumAge: 60 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Boston Medical Center, Rheumatology Clinic city: Boston state: Massachusetts zip: 02118 country: United States name: Jean Liew, MD MS role: CONTACT phone: 617-358-9655 email: jwliew@bu.edu lat: 42.35843 lon: -71.05977 hasResults: False
nctId: NCT06385262 id: Pro00114645 briefTitle: TOP 2301: Neoadjuvant Chemo for NSCLC overallStatus: NOT_YET_RECRUITING date: 2024-07-01 date: 2026-06-30 date: 2028-06-30 date: 2024-04-26 date: 2024-04-29 name: Duke University class: OTHER name: Regeneron Pharmaceuticals briefSummary: In this open-label, two-arm, randomized phase 2 clinical trial, patients with clinical stage 1B-3A non-small cell lung cancer (NSCLC) will receive neoadjuvant chemotherapy and cemiplimab every 3 weeks for 3 cycles with or without alirocumab every 4 weeks prior to surgery.
The study hypothesis is that the addition of alirocumab to neoadjuvant chemoimmunotherapy will make tumor cells more immunogenic to cytotoxic T cells, resulting in an increase in complete pathologic responses in surgically resected tumor. conditions: Non Small Cell Lung Cancer studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 126 type: ESTIMATED name: Alirocumab name: Cemiplimab name: Chemotherapy measure: Compare pathologic complete response (pCR) rate for neoadjuvant chemotherapy plus cemiplimab versus chemotherapy, cemiplimab, and alirocumab. measure: Assess the preliminary efficacy of chemotherapy and cemiplimab with alirocumab as determined by objective response rate (ORR) measure: Assess the preliminary efficacy of chemotherapy and cemiplimab with alirocumab as determined by disease-free survival (DFS) measure: Assess the preliminary efficacy of chemotherapy and cemiplimab with alirocumab as determined by overall survival (OS) measure: Determine the safety of neoadjuvant chemotherapy and cemiplimab with alirocumab in early-stage non-small cell lung cancer (NSCLC) measure: Determine the tolerability of neoadjuvant chemotherapy and cemiplimab with alirocumab in early-stage non-small cell lung cancer (NSCLC) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06385249 id: NAV-0012 briefTitle: An Evaluation of Navina Mini, a New Trans-anal Irrigation (TAI) Device in Children and Adolescents overallStatus: RECRUITING date: 2024-04-03 date: 2024-10 date: 2024-12 date: 2024-04-26 date: 2024-04-26 name: Wellspect HealthCare class: INDUSTRY briefSummary: The study is designed to deliver further information on clinical benefit, patients' satisfaction, and perception of handling and to confirm safety of Navina Mini when used in children and adolescents. conditions: Bowel Dysfunction studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 27 type: ESTIMATED name: Navina Mini measure: Overall patient satisfaction measure: Incomplete bowel emptying measure: Episodes of fecal incontinence measure: Level of independence measure: Perception of handling of the device measure: Safety outcome sex: ALL minimumAge: 3 Years maximumAge: 17 Years stdAges: CHILD facility: H.K.H. Kronprinsessan Victorias Barn- och ungdomssjukhus Universitetssjukhuset status: RECRUITING city: Linköping country: Sweden name: Peter Wide role: CONTACT phone: +46101031341 email: Peter.Wide@regionostergotland.se name: Jenny Axelsson role: CONTACT phone: +46101032432 email: jenny.axelsson@regionostergotland.se lat: 58.41086 lon: 15.62157 hasResults: False
nctId: NCT06385236 id: 804913 id: R01HL161362 type: NIH link: https://reporter.nih.gov/quickSearch/R01HL161362 briefTitle: Leveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping acronym: EPIPHANY overallStatus: RECRUITING date: 2024-02-19 date: 2027-06-30 date: 2028-01-31 date: 2024-04-26 date: 2024-04-26 name: University of California, San Diego class: OTHER name: Mayo Clinic name: Yale University name: University of Arizona name: Harvard University name: Brigham and Women's Hospital name: National Heart, Lung, and Blood Institute (NHLBI) briefSummary: In this study, a new method will be used to evaluate response to 2 approved biologic therapies, and assess how well each patient responds to each asthma treatment. This study will measure the response to these treatments using genomic and biologic measurements obtained from participants biosamples.
By evaluating response to 2 different biologic therapies, this study has the potential to provide an in-depth understanding of the mechanisms underlying severe asthma that will inform and change treatment decisions, and may ultimately lead to a change in the way that asthma patients are evaluated for potential personalized therapies and maximize the probability that the subject will respond to treatment. conditions: Moderate to Severe Asthma studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: The study is significant in determining molecular disease endotypes in a large group of moderate to severe asthmatics. By evaluating within-person genomic level changes and response to 2 different biologic therapies, this study has the potential to provide an in-depth understanding of the mechanisms underlying severe asthma that will inform and change treatment decisions. primaryPurpose: TREATMENT masking: NONE count: 120 type: ESTIMATED name: Dupilumab name: Benralizumab measure: Predicting asthma outcomes and therapeutic responses measure: Responses to the biologic therapies at the single cell level measure: Unique asthma subgroups clinical and molecular endotype approaches measure: Asthma Control Questionnaire (ACQ) measure: CompEx events measure: Asthma Quality of Life Questionnaire (AQLQ) measure: Forced expiratory volume in 1 second (FEV1) sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Mayo Clinic status: RECRUITING city: Scottsdale state: Arizona zip: 85259 country: United States name: Karalyn Folmes, Ph.D. role: CONTACT phone: 480-301-4298 email: folmes.karalyn@mayo.edu name: Gene R Bleecker, MD role: PRINCIPAL_INVESTIGATOR name: Deborah A Meyers, PhD role: PRINCIPAL_INVESTIGATOR lat: 33.50921 lon: -111.89903 facility: University of California, San Diego status: RECRUITING city: La Jolla state: California zip: 92093 country: United States name: Asthma Research Team role: CONTACT phone: 619-431-0995 email: asthma@health.ucsd.edu name: Kelan Tantisira, MD role: PRINCIPAL_INVESTIGATOR name: Praveen Akuthota, MD role: PRINCIPAL_INVESTIGATOR lat: 32.84727 lon: -117.2742 facility: Yale University status: RECRUITING city: New Haven state: Connecticut zip: 06520 country: United States name: Katherine Spaulding role: CONTACT phone: 203-737-5572 email: katherine.spaulding@yale.edu name: Geoffrey L Chupp, MD role: PRINCIPAL_INVESTIGATOR lat: 41.30815 lon: -72.92816 hasResults: False
nctId: NCT06385223 id: DSRB 2023/00680 briefTitle: A Novel Individualized Connectome-guided Approach for Precision Intermittent Theta Burst Stimulation for Depression overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2026-07-01 date: 2026-12-31 date: 2024-04-25 date: 2024-04-25 name: Institute of Mental Health, Singapore class: OTHER name: National University of Singapore briefSummary: The Investigators propose to carry out a randomized, double-blind trial to compare the clinical efficacy of an individualized connectome-guided accelerated iTBS vs an anatomically-guided (Beam F3) accelerated iTBS. The study team will recruit both inpatients and outpatients who had been referred for TMS for the treatment of depression. conditions: Depression studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: OUTCOMES_ASSESSOR count: 70 type: ESTIMATED name: Beam F3 targeted accelerated iTBS name: Individualized connectome-guided accelerated iTBS measure: Montgomery-Åsberg Depression Rating Scale measure: Quick Inventory of Depressive Symptomatology (16-Item) (Self-Report) measure: Montreal Cognitive Assessment (MoCA) measure: EQ-5D (EuroQol) measure: Quality of Life Enjoyment and Satisfaction Questionnaire Short form (Q-LES-QS-SF) measure: TMS induced changes in resting-fMRI functional connectivity sex: ALL minimumAge: 21 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06385210 id: 22SM7855 briefTitle: Barriers to Routine Surgical Video Recording overallStatus: COMPLETED date: 2024-04-01 date: 2024-04-24 date: 2024-04-24 date: 2024-04-25 date: 2024-04-26 name: Imperial College London class: OTHER briefSummary: In order to improve the implementation of routine surgical video recording, the researchers want to understand what the challenges associated with the uptake of this technology are. The aim of this study is to explore the barriers faced by key stakeholders including the surgical care team, information governance, and patients within the field of surgical video reporting. The data from this qualitative study will allow the researchers to understand better the challenges associated with uptake of surgical video recording. This will allow the researchers to develop strategies to overcome these challenges and subsequently improve uptake of surgical video recording which will promote safer and more transparent surgery. conditions: Minimally Invasive Surgery conditions: Laparoscopic Surgery studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: OTHER masking: NONE count: 15 type: ACTUAL name: Semi structured interviews measure: Stakeholder perceived barriers to surgical video recording sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Department of Surgery and Cancer city: London zip: W2 1NY country: United Kingdom lat: 51.50853 lon: -0.12574 hasResults: False
nctId: NCT06385197 id: 170886-HMO-CTIL briefTitle: Improving the Effect of Multiple Sclerosis Drugs by Chronobiology overallStatus: COMPLETED date: 2022-05-08 date: 2023-06-01 date: 2023-06-02 date: 2024-04-25 date: 2024-04-25 name: Hadassah Medical Organization class: OTHER briefSummary: A trial for evaluating the ability to improve the effect of dimethyl fumarate in patients with Multiple Sclerosis (MS) by chronobiology A controlled-randomization dosing regimen administered to patients with MS and provided by a designated app. The treatment limitations of time interval is pre-defined according to approved therapeutic windows. conditions: Multiple Sclerosis studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: A controlled-randomization dosing regimen administered to patients with MS and provided by a designated app. The treatment limitations of time interval is pre-defined according to approved therapeutic windows. primaryPurpose: DEVICE_FEASIBILITY masking: NONE count: 8 type: ACTUAL name: App randomizing dosing regimen measure: safety assessment sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT facility: Hadassah Medical Center city: Jerusalem country: Israel lat: 31.76904 lon: 35.21633 hasResults: False
nctId: NCT06385184 id: NCR234859 briefTitle: Social & QoL Behaviors in Parkinson's Disease overallStatus: RECRUITING date: 2024-03-08 date: 2025-12-31 date: 2025-12-31 date: 2024-04-25 date: 2024-04-25 name: Gregory Wallace class: OTHER briefSummary: Adults with Parkinson's Disease experience an array of challenges and changes in daily living, behaviors, and functioning throughout the progression of their condition. The investigators want to learn more about the effects of Parkinson's Disease on individuals' social behavior and quality of life (QoL) compared to people of the same age without Parkinson's Disease. conditions: Parkinson Disease studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: CROSS_SECTIONAL count: 500 type: ESTIMATED name: No Intervention measure: Subjective Quality of Life measure: Social Behavior measure: Activities of Daily Living measure: Mental Health measure: Cognition sex: ALL minimumAge: 40 Years stdAges: ADULT stdAges: OLDER_ADULT facility: The George Washington University status: RECRUITING city: Washington state: District of Columbia zip: 20052 country: United States name: Gregory Wallace, PhD role: CONTACT phone: 202-994-8285 email: ladn@gwu.edu lat: 38.89511 lon: -77.03637 hasResults: False
nctId: NCT06385171 id: FFA-BTX-1 briefTitle: Assessing the Impact of Botulinum Toxin Type A on Facial Wrinkles: A Comprehensive Clinical Investigation overallStatus: NOT_YET_RECRUITING date: 2024-07-01 date: 2026-08-01 date: 2027-01-05 date: 2024-04-25 date: 2024-04-25 name: Global Aesthetics LLC class: OTHER briefSummary: A study conducting to see how well a treatment called Botulinum Toxin Type A works for reducing facial wrinkles. The study will help us understand if this treatment is safe and effective for making wrinkles on the face less noticeable. conditions: Wrinkle studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 500 type: ESTIMATED name: Botulinum toxin type A measure: Change in facial wrinkles and Lines measure: Facial Appearance measure: Assessment of Wrinkle Severity measure: Assessment of Skin Reaction sex: ALL minimumAge: 20 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Global Aesthetics LLC city: Cisco state: Texas zip: 76437 country: United States lat: 32.38819 lon: -98.97923 facility: Global Aesthetics LLC city: Lubbock state: Texas zip: 79413 country: United States name: Otis Scroggins, BS, CNA role: CONTACT phone: 806-370-7428 email: fakefaceaesthetics@gmail.com lat: 33.57786 lon: -101.85517 hasResults: False